Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-22T16:39:20.110Z Has data issue: false hasContentIssue false
  • English
  • Français

The Clinical State, Sleep and Amine Metabolism of a Tranylcypromine (‘Parnate’) Addict

Published online by Cambridge University Press:  29 January 2018

J. Le Gassicke ,
G. W. Ashcroft ,
D. Eccleston ,
J. I. Evans ,
I. Oswald  and
E. B. Ritson
J. Le Gassicke
Affiliation:
St. George's Hospital, Morpeth, Northumberland
G. W. Ashcroft
Affiliation:
Department of Pharmacology, University of Edinburgh
D. Eccleston
Affiliation:
Medical Research Council Grantee, Department of Pharmacology, University of Edinburgh
J. I. Evans
Affiliation:
Professorial Unit, Royal Edinburgh Hospital
I. Oswald
Affiliation:
Department of Psychological Medicine, University of Edinburgh
E. B. Ritson
Affiliation:
Royal Edinburgh Hospital
Get access Rights & Permissions [Opens in a new window]

Extract

A number of drugs capable of mono-amine oxidase inhibition have been marketed with the claim that they alleviate depressive illness. One of these is tranylcypromine (‘Parnate’), which has won notoriety on account of the severe headache experienced by those receiving the drug when they also eat ripe cheese (Lancet, 1964). In chemical structure, it is related to amphetamine. Amphetamine is a drug of addiction, and addiction to tranylcypromine was therefore to be expected. A preliminay notice of the present patient has already been published (Le Gassicke, 1962).

Type
Research Article
Information
The British Journal of Psychiatry , Volume 111 , Issue 473 , April 1965 , pp. 357 - 364
Copyright
Copyright © Royal College of Psychiatrists, 1965 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ashcroft, G. W., Crawford, T. B. B., Binns, J. K., and McDougall, E.J. (1964). “Estimation of 5-hydroxy-tryptamine in human blood.” Clin. Chim. Acta, 9, 364–369.Google Scholar
Berger, J., and Oswald, I. (1962). “Effects of sleep deprivation on behaviour, subsequent sleep, and dreaming.” J. Ment. Sci., 108, 457–465.Google Scholar
Dement, W. (1960). “The effect of dream deprivation.” Science, 131, 1705–1707.Google Scholar
Dement, W. (1963). Communication to Annual Convention of American Psychological Association, Philadelphia, August, 1963.Google Scholar
Dement, W. and Klettman, N. (1957). “Cyclic variations in EEG during sleep and their relation to eye movements, body motility and dreaming.” Electroenceph. clin. Neurophysiol., 9, 673–690.CrossRefGoogle Scholar
Feinberg, I., Koresko, R. L., Gottlieb, F., and Wender, P. H. (1964). “Sleep electroencephalographic and eye-movement patterns in schizophrenic patients.” Compr. Psychiat., 5, 44–53.CrossRefGoogle Scholar
Hess, S. M., and Udenfriend, S. (1959). “A fluorometric procedure for the measurement of tryptamine in tissues.” J. Pharm. exp. Ther., 127, 175–177.Google Scholar
Lancet (1964). “The cheese reaction.” Lancet, i, 540.Google Scholar
Le Gassicke, J. (1963). “Tranylcypromine.” Ibid., i, 270.Google Scholar
Long, R. F., and Lessin, A. W. (1962). “Inhibition of 5-hydroxytryptamine uptake by platelets in vitro and in vivo.” Biochem. J., 82, 4–5.Google Scholar
Marshall, E. F., Stirling, G. S., Tait, A. C., and Todrick, A. (1960). “The effect of iproniazid and imipramine on the blood platelet 5-hydroxytryptamine level in man.” Brit. J. Pharmacol., 15, 35–41.Google Scholar
Oates, J. A. (1961). “Measurement of urinary tryptamine, tyramine and serotonin.” Meth. med. Res., 9, 169–174.Google Scholar
Oswald, I. (1964). “Physiology of sleep accompanying dreaming”, in Scientific Basis of Medicine Annual Reviews (ed. Ross, James Paterson Sir). London.Google Scholar
Oswald, I., Berger, R. J., Evans, J. I., and Thaoore, V. R. (1964). “Effect of 1-tryptophan upon human sleep.” Electroenceph. clin. Neurophysiol., 16, 603.Google Scholar
Oswald, I., Berger, R. J., Evans, J. I., and Thaoore, V. R. and Thacore, V. R. (1963). “Amphetamine and phenometrazine addiction, physiological abnormalities in the abstinence syndrome.” Brit. med. J., 2, 427–431.Google Scholar
Pletscher, A., and Bernstein, A. (1958). “Increase of 5-hydroxytryptamine in blood platelets by isopropylisonicotinic acid hydrazide.” Nature, 181, 1133–1134.CrossRefGoogle Scholar
Rechtschaffen, A., and Maron, L. (1964). “Effect of amphetamine on the sleep cycle.” Electroenceph. clin. Neurophysiol., 16, 438–444.Google Scholar
Wolpert, E. A., Dement, W. C., Mitchell, S. A., and Fisher, C. (1963). “Nocturnal sleep of narcolepsy.” Ibid., 15, 599–609.Google Scholar
Schwartz, B. A., and Gilbaud, G. (1964). “L'EEG du sommeil nocturne en neurochirurgie.” Rev. Neurol., 110, 307–308.Google Scholar
Sjoerdsma, A., Oates, J. A., Zaltzman, P., and Udenfriend, S. (1959). “Identification and assay of urinary tryptamine: application as an index of monoamine oxidase inhibition in man.” J. Pharm. exp. Ther., 126, 217–222.Google Scholar
Udenfriend, S., Bogdanski, D. F., and Weissbach, H. (1955). “Fluorescence characteristics of 5-hydroxytryptamine (serotonin).” Science, 122, 972–973.Google Scholar
Udenfriend, S., Bogdanski, D. F., and Weissbach, H., Trrus, E., and Weissbach, H. (1955). “Identification of 5-hydroxy-3-indoleacctic acid in normal urine and method for its assay.” J. biol. Chem., 216, 499–505.Google Scholar
Weissbach, H., King, W., Sjoerdsma, A., and Udenfriend, S. (1959). “Formation of indole-3-acetic acid and tryptamine in animals.” Ibid., 234, 81–86.Google Scholar
Williams, H. L., Hammack, J. T., Daly, R. L., Dement, W. C., and Lubin, A. (1964). “Responses to auditory stimulation, sleep loss and the EEG stages of sleep.” Electroenceph. clin. Neurophysiol., 16, 269–279.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.